Longo A
UTIC-Arsénio Cordeiro, Hospital de Santa Maria, Lisboa.
Rev Port Cardiol. 1993 Nov;12 Suppl 4:53-9, 9.
Beta-blockers are generally considered contra-indicated in heart failure. Some authors have claimed that in dilated cardiomyopathy and in pos myocardial infarction patients with heart failure beta-blockers can improve symptoms and survival. These trials and their conclusions are revised and the rationale of pathologic physiology of heart failure for this treatment are discussed.
β受体阻滞剂通常被认为是心力衰竭的禁忌药物。一些作者声称，在扩张型心肌病以及心肌梗死后心力衰竭患者中，β受体阻滞剂可改善症状并提高生存率。本文对这些试验及其结论进行了修订，并讨论了心力衰竭病理生理学中该治疗方法的理论依据。
